AERI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AERI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Aerie Pharmaceuticals's retained earnings for the quarter that ended in Sep. 2022 was $-1,188.0 Mil.
Aerie Pharmaceuticals's quarterly retained earnings declined from Mar. 2022 ($-1,141.8 Mil) to Jun. 2022 ($-1,161.2 Mil) and declined from Jun. 2022 ($-1,161.2 Mil) to Sep. 2022 ($-1,188.0 Mil).
Aerie Pharmaceuticals's annual retained earnings declined from Dec. 2019 ($-896.0 Mil) to Dec. 2020 ($-1,079.1 Mil) and declined from Dec. 2020 ($-1,079.1 Mil) to Dec. 2021 ($-1,153.9 Mil).
The historical data trend for Aerie Pharmaceuticals's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerie Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial | -461.73 | -696.42 | -896.00 | -1,079.10 | -1,153.91 |
Aerie Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Retained Earnings | Get a 7-Day Free Trial | -1,199.44 | -1,153.91 | -1,141.84 | -1,161.21 | -1,188.04 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Aerie Pharmaceuticals (NAS:AERI) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Peter Frederick Lang | officer: Chief Financial Officer | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Raj Kannan | director, officer: Chief Executive Officer | C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451 |
Jeffrey Calabrese | officer: Vice President of Finance | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Kathleen Mcginley | officer: CHRO & VP, Corp Services | 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618 |
Christopher Staten | officer: Interim CFO | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Casey C. Kopczynski | officer: Chief Scientific Officer | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Peter J Mcdonnell | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Gerald D. Cagle | director | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Foresite Capital Fund Ii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
David Hollander | officer: Chief R&D Officer | C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Richard J Rubino | officer: Chief Financial Officer | |
Vicente Jr Anido | director, officer: Chief Executive Officer | 1621 BAYSIDE DR, CORONA DEL MAR CA 92625 |
Foresite Capital Management Iv, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Thomas A Mitro | officer: President and COO | 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618 |
From GuruFocus
By Business Wire Business Wire • 02-24-2022
By PRNewswire PRNewswire • 08-25-2022
By Business Wire Business Wire • 03-18-2022
By Business Wire Business Wire • 04-06-2022
By Business Wire Business Wire • 08-24-2022
By PRNewswire PRNewswire • 10-25-2022
By GuruFocus Research GuruFocus Editor • 01-27-2023
By Business Wire Business Wire • 08-25-2022
By GuruFocus Research GuruFocus Editor • 01-25-2023
By Business Wire Business Wire • 04-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.